THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Clinical trials for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) explained in plain language.
Never miss a new study
Get alerted when new THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) trials appear
Sign up with your email to follow new studies for THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug cuts dangerous blood clots in rare genetic disorder
Disease control CompletedThis study tested a new medicine called BAX 930 in 52 people born with severe TTP, a rare blood-clotting disorder. The medicine replaces a missing enzyme to prevent or treat dangerous flare-ups. Participants received either BAX 930 or standard care for 6 months, then switched, fo…
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Phase: PHASE3 • Sponsor: Baxalta now part of Shire • Aim: Disease control
Last updated May 17, 2026 07:56 UTC
-
New drug may reduce need for plasma exchange in rare blood disorder
Disease control CompletedThis study tested a drug called TAK-755 in 29 adults with immune-mediated thrombotic thrombocytopenic purpura (iTTP), a rare condition causing dangerous blood clots. The goal was to see if TAK-755, along with standard immune-suppressing drugs, could help patients recover without …
Matched conditions: THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP)
Phase: PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated May 06, 2026 16:01 UTC